Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Large Increase in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 7,670,000 shares, an increase of 40.5% from the October 15th total of 5,460,000 shares. Approximately 5.6% of the company’s shares are short sold. Based on an average daily trading volume, of 31,930,000 shares, the short-interest ratio is currently 0.2 days.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC raised its position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 335,373 shares of the company’s stock after acquiring an additional 242,358 shares during the period. Acadian Asset Management LLC owned approximately 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent reporting period. 82.26% of the stock is currently owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Trading Down 6.4 %

TNXP traded down $0.01 during midday trading on Friday, hitting $0.13. The company’s stock had a trading volume of 10,509,191 shares, compared to its average volume of 10,158,421. Tonix Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $22.14. The firm has a 50-day moving average price of $0.15 and a two-hundred day moving average price of $1.44. The company has a current ratio of 1.15, a quick ratio of 0.72 and a debt-to-equity ratio of 0.13. The firm has a market cap of $17.99 million, a P/E ratio of 0.00 and a beta of 2.06.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 158.64%. On average, research analysts anticipate that Tonix Pharmaceuticals will post -18 earnings per share for the current year.

Analysts Set New Price Targets

TNXP has been the topic of several recent analyst reports. Alliance Global Partners upped their price objective on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 22nd. StockNews.com started coverage on Tonix Pharmaceuticals in a research note on Wednesday. They set a “sell” rating on the stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.